Certara’s Post

Zuellig Pharma’s Senior Vice President of Clinical Reach Giuseppe Leo recently guested on Biztech.asia’s C-Suite Conversations Show, where he shared about evolving trends in the pharmaceutical and clinical trials space and how Zuellig Pharma’s Clinical Reach business is poised to meet the changing needs of the life sciences industry.   Amidst a complex, fast-moving environment, drug development has grown phenomenally in the last decade, and the regulatory landscape for clinical trials has become increasingly challenging to navigate.   In his conversation with Brian Fernandez, Giuseppe discussed how our Clinical Reach division was established over 15 years ago in response to unmet needs within the drug development and innovation space. He also elaborated on Zuellig Pharma’s proven expertise and foothold in Asia, which has enabled us to evolve with growing trends such as cold chain management and greater agility when running global trials.   Watch the full interview here: https://lnkd.in/gXBzkD6H   #ZuelligPharmaClinicalReach #ClinicalTrials #ColdChainManagement #MakingHealthcareMoreAccessible 

REGISTER NOW 📆 C-Path's Predictive Safety Testing Consortium is delighted to announce its second public workshop on evidentiary considerations for regulatory assessment and qualification of complex in vitro models - CIVMs. Health authorities, academia professionals, model developers, and representatives from the pharmaceutical industry are encouraged to participate in this workshop. It offers a valuable platform for attendees to engage in discussions and deliberations regarding the evidentiary considerations essential for regulatory assessment and qualification of CIVMs. Through collaborative efforts, attendees will strive to reach a consensus on the standards and features necessary to enhance the performance of CIVMs as a reliable tool for drug development and regulatory assessment. The meeting agenda features sessions led by key opinion leaders, who will address general considerations for qualification. Additionally, interactive breakout sessions will concentrate on various organ systems and disease models. During these breakouts, participants will actively engage in discussions and deliberations to explore the evidentiary considerations crucial for regulatory assessment and qualification of complex in vitro models. Join us September 26 - 27, 2024 in Bethesda, Maryland. Register now: https://lnkd.in/gKXn8R4e. #CPath #PSTC #CIVM #workshop #drugdevelopment #datasharing #regulatoryscience #collaboration #globalhealth

Webinars are everywhere these days, but I promise you this one’s worth it! 💡 💡 💡 Thermo Fisher Scientific is hosting an exclusive session that explores an innovative solution—integrating our practical strategies for simplifying the development journey with our Accelerator™ Drug Development providing CDMO and CRO efforts under one seamless umbrella. This is your opportunity to discover how to streamline operations, enhance quality, and achieve milestones faster than ever before! 💊 📈 🔊 During this webinar, we will share key insights from preliminary findings by the TUFTS Center for the Study of Drug Development. We will delve into how a comprehensive model that unites CDMO and CRO services which can significantly impact the expected Net Present Value (eNPV) of drug development programs. Don't miss out on this chance to see how we're revolutionizing the industry. Feel free to DM me for more details or any questions on how we can help you succeed! 💬🤝 Click here to tune in 🚀! https://lnkd.in/ecVDtWhD #Webinar #DrugDevelopment #ThermoFisher #CDMO #CRO #Biotech #ClinicalResearch #DrugDiscovery #LifeSciences #PharmaSuccess #PharmaWebinar

🌍 ProductLife Group is heading to CPHI Milan 2024! From October 8-10, our team will be attending CPHI Milan, connecting with industry leaders and exploring the latest trends in the pharmaceutical sector. We're excited to discuss how our expertise in regulatory affairs and product lifecycle management can help drive innovation and compliance for your business. #CPHI2024 #pharmainnovation #regulatoryaffairs #pharma #lifescience

📢 Last week, we launched the State of the Discovery Nation 2024 report, in partnership with the UK BioIndustry Association and the Association of the British Pharmaceutical Industry. Download here: https://hubs.li/Q02x3D3L0 The State of the Discovery Nation 2024 examines the sector’s challenges. It shows what is needed to secure a rich medicines pipeline and build on the UK’s global leadership in #LifeSciences. This includes: ---▶️ Creating strong partnerships with translational experts, who can take early-stage discoveries through to late-stage clinical development so #SMEs can de-risk assets for investment wherever they are in the UK ---▶️ Providing high-quality #laboratory facilities and incubator spaces for companies at all stages of maturity ---▶️ Make funds available, visible and accessible to support SMEs. Leverage private/public initiatives to co-develop pipelines of high-quality #FitToFund companies. In partnership with: Medicines Discovery Catapult | BioIndustry Association (BIA) | The Association of the British Pharmaceutical Industry (ABPI) #DrugDiscovery #SoDN2024 #Collaboration #SME

This week, the Faculty of Pharmaceutical Medicine and Paddington Life Sciences, supported by Egality, held a roundtable on Making the UK a Global Leader in Inclusive and Diverse Clinical Trials.    It was truly cross-sector, with regulators, industry, third sector and the NHS represented. This meant for a dynamic discussion where we could identify common challenges, and opportunities to collaborate and drive change. 🤝 The UK has huge potential to be a leader in inclusive and diverse clinical trials, but this requires urgent action, and a commitment to joint-working. The report with recommendations will follow in the new year. Stay tuned! ✨ #UKlifesciences #diverseclinicaltrials    

Coming up next week! Make sure to register for the last #FRPanorama webinar of 2024: How novel technologies are facilitating the sharing of regulatory data between reference and reliant agencies. #accumulussynergy #accumulus #FRPath #regulatoryreliance

It is an honor to announce that I have successfully attended and received certification from the FDA “Regulatory Education for Industry (REdI) Annual Conference 2024: Innovation in Medical Product Development.” The conference, held on May 29-30, 2024, was an incredible opportunity to learn directly from the FDA’s regulatory experts in drugs, devices, and biologics. The sessions provided a robust foundation in the FDA’s regulatory requirements and current activities. A special thanks to the keynote speakers: ✶ Robert M. Califf, M.D., MACC - Commissioner of Food and Drugs ✶ Patrizia Cavazzoni, M.D. - Director, Center for Drug Evaluation and Research (CDER) ✶ Jeff Shuren, M.D., J.D. - Director, Center for Devices and Radiological Health (CDRH) ✶ Peter Marks, M.D., Ph.D. - Director, Center for Biologics Evaluation and Research (CBER) I attended the Drugs track, which covered groundbreaking advances and innovations in drug development, including: ➢ Enhancing Clinical Trial Innovation ➢ AI in Drug Development ➢ Reimagining Clinical Research ➢ Advanced Manufacturing Technologies (AMT) Designation Program ➢ Innovative Approaches to Emerging Threats I am incredibly grateful to the FDA and everyone involved in organizing this conference for providing such a valuable and enriching experience. This knowledge will greatly contribute to my work in the field of medical product development. FDA CDER Small Business and Industry Assistance (SBIA) Kevin Bugin Tala Fakhouri Kristina Lauritsen Alyson (Forman) Karesh Jonathan Resnick, M.D. , FACG, FASGE Ranjani Prabhakara, Ph.D. Jill Furman #FDA #REdIConference #MedicalProductDevelopment #Innovation #DrugDevelopment #ClinicalTrials #AI #RegulatoryAffairs

We are thrilled to announce our collaboration with LB Research srl - Clinical Trials Management at the highly anticipated Simposio AFI in 2024! With our innovative solutions and the expertise of LB Research, we are confident that we will make a significant impact. Take advantage of learning more about our groundbreaking solutions at booth #1. We are excited to meet you there and explore how we can help you achieve your goals. Let's make the most of this incredible event together! https://lnkd.in/dsc6hDY3 #clinicalresearch #healthcaredata #healthcareit #healthcaresoftware #data #healthcare #pharmaceuticals #digitalhealthcare #pharmaceuticaltechnology #clinicalresearch #clinicaltrials #digitalhealth #healthtechnology #healthtech #clinicalresearch #clinical #cro #clinicaldata #clinicaltrialmanagement #clinicalstudies #clinicaldataplatforms #remotehealthcare #remotehealth #clinicaloperations #clinicaldevelopment #clinicaloperations #clinicaldata #remotemonitoring #datamanagementplatform #datamanagement #pharma #lifescience #rwe #rwd #epro #sops #etmf #edc #sdv #edc #cra #rtsm #sae #uat #gcp #qa #ecoa #iwrs #esource #econsent

We are proud to share that Dr. Art Hsing-Mao Chu, CEO of T-E Meds, an affiliate company of Immunwork, was invited to present at the BIO Asia–Taiwan 2024 conference. Dr. Chu's presentation, titled "Drug Bundle-Based #ADC Platform: Achieving Site-Specific Conjugation, DAR of 8 or 12, and Dual Payloads," highlighted our innovative technology. The talk emphasized how our novel #ADC platform streamlines the #CMC process and generates high-DAR, dual-payload ADCs with superior efficacy and outstanding stability. These advancements position us at the forefront of therapeutic development. We welcome #partnerships to further advance these groundbreaking technologies and transform patient care. Let's innovate together! #BIOAsiaTaiwan #ADCTechnology #BiotechInnovation #Partnerships #Immunwork #TEMeds #Pharmaceuticals #HealthcareInnovation